Clinical recommendation	Evidence rating	References
Pramlintide (Symlin) has been shown to cause a statistically significant weight loss and reduction in A1C levels when used in conjunction with insulin, metformin (Glucophage), or a sulfonylurea.	B (weight loss)	^2,11–14
	C (other outcomes)	^2,11–14
Exenatide (Byetta) has been shown to cause a statistically significant weight loss and reduction in fasting plasma glucose, postprandial glucose, and A1C levels when used in conjunction with metformin or a sulfonylurea.	B (weight loss)	^17–20
	C (other outcomes)	^17–20